Wegovy, Ozempic Targeted by US for Medicare Price Cuts

The transcript discusses the impact of IRA negotiations on Medicare, focusing on potential price cuts for Novo Nordisk and the implications for Eli Lilly. It highlights the challenges faced by Novo Nordisk due to the need to compensate the federal government for price differences, while Eli Lilly might benefit from unchanged rebate structures. The discussion also covers the broader industry response to the IRA's price negotiation framework.

What are the implications of the lack of significant coverage for obesity treatments on Novo Nordisk's business?

In what ways could Eli Lilly benefit from the changes in pricing for Novo's drugs?